Novel research strategies of Benzimidazole derivatives: A review

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 10, 2013, Pages 1421-1447

  Barot, Kuldipsinh P ^a   Nikolova, Stoyanka ^b   Ivanov, Illiyan ^b   Ghate, Manjunath D ^a  

^a NIRMA UNIVERSITY   (India)

^b UNIVERSITY OF PLOVDIV   (Bulgaria)

Author keywords

Benzimidazoles; Chemistry; Early rationality; Pharmacological activities

Indexed keywords

1[H] BENZIMIDAZOLE 4 CARBOXAMIDE DERIVATIVE; 2 ((3 4 DIMETHOXYPYRIDIN 2 YL) METHYLSULFINYL) 5 METHOXY 6 METHYL 1H BENZO[D]IMIDAZOLE 70; 2 (2' BENZIMIDAZOLYL) AMINO 4 METHYL THIAZOL 68; 5 METHOXY 2 (2 (2 2 6 6 TETRAMETHYLPIPERIDIN 1 YL)ETHYLTHIO) 1H BENZO[D]IMIDAZOLE 69; 6 AZA BENZIMIDAZOLONE DERIVATIVE; 9 (DIETHYLAMINO ETHYLENE) 2 PHENYL IMIDAZO [1 2 A] BENZIMIDAZOLE 66; ALBENDAZOLE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; CAMBENDAZOLE; CYCLIN DEPENDENT KINASE; ESOMEPRAZOLE; FENBENDAZOLE; GLUCAGON RECEPTOR; IMIDAZOLE DERIVATIVE; LANSOPRAZOLE; LEMINOPRAZOLE; MEBENDAZOLE; N ALLYL 1 ETHYL 8 ((5 FLUORO 6 METHOXY 1H BENZO [D] IMIDAZOL 2 YLSULFINYL) METHYL) N METHYL 1 2 3 4 TETRAHYDROQUINOLIN 4 AMINE 65; OMEPRAZOLE; OXFENDAZOLE; OXIBENDAZOLE; PANTOPRAZOLE; PARBENDAZOLE; RABEPRAZOLE; SODIUM GLUCOSE COTRANSPORTER; TIABENDAZOLE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTICOAGULATION; ANTICONVULSANT ACTIVITY; ANTIDEPRESSANT ACTIVITY; ANTIDIABETIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIULCER ACTIVITY; ANTIVIRAL ACTIVITY; BIOLOGICAL ACTIVITY; HUMAN; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; STRUCTURE ACTIVITY RELATION; TAUTOMER;

BENZIMIDAZOLES; DRUG DISCOVERY; HUMANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84881538669     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/13895575113139990072     Document Type: Review

References (250)

1. Afaf, H.E.; Fahmy, H.H.; Abdelwal, S.H. Chemistry of benzimidazole nucleus. Molecules, 2000, 5, 1429.
2. Congiu, C.; Cocco, M.T.; Onnis, V. Design, synthesis, and in vitro antitumor activity of new 1,4-diarylimidazole-2-ones and their 2- thione analogues. Bioorg. Med. Chem. Lett., 2008, 18, 989-993.
3. Venkatesan, A.M.; Agarwal, A.; Abe, T.; Ushirogochi, H.O. 5,5,6- Fused tricycles bearing imidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of beta-lactamases. Bioorg. Med. Chem., 2008, 16, 1890-1902.
4. Velik, J.; Baliharova, V.; Fink-Gremmels, J. Benzimidazole drugs and modulation of biotransformation enzymes. Research in Veterinary Science, 2004, 75, 95-108.
5. Nantermet, P.G.; Barrow, J.C.; Lindsley, S.R.; Young, M.; Mao, S. Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group. Bioorg. Med. Chem. Lett., 2004, 14, 2141-2145.
6. Adams, J.L.; Boehm, J.C.; Gallagher, T.F.; Kassis, S.; Webb, E.F. Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity. Bioorg. Med. Chem. Lett., 2001, 11, 2867-2870.
7. Woolley, D.W. Therapeutic strategies of heterocyclic nucleus. J. Biol. Chem., 1944, 152, 225.
8. Brink, N.G.; Flokers, K. Biochemistry of vitamin B12 with 5,6- dimethylbenzimidazole as the degradation product. J. Am. Chem. Soc., 1949, 71, 2951.
9. Emerson, G.; Brink, N.G.; Holly, F.W. The detection of reverse mutations at the mtr locus in Neurospora and evidence for possible intragenic (second site) suppressor mutations. J. Am. Chem. Soc., 1950, 72, 3084.
10. McKellar, Q.A.; Scott, E.W. The benzimidazole anthelmintic agents-a review. J. Vet. Pharmacol. Ther., 1990, 13, 223.
11. Spasov, A.A.; Yozhitsa, I.N.; Bugaeva, L.I.; Anisimova, V.A. Biological activities of benzimidazoles and thiabendazoles. Pharm. Chem. J., 1999, 33, 232.
12. Rossignol, J.F.; Maisonneuve, H. Benzimidazoles in the treatment of trichuriasis: a review. Ann. Trop. Med. Parasitol., 1984, 78, 135.
13. Patil, A.; Ganguly, S.; Surana, S. Benzimidzoles and benzotriazoles in the treatment of viral infections. Rasayan J. Chem., 2008, 1, 447.
14. Dubey, A.K.; Sanyal, P.K. Antihistaminic agents and their therapeutic potentials. Online Vet. J., 2010, 5, 63.
15. Boiani, M.; González, M. Imidazole and benzimidazole derivatives as chemotherapeutic agents. Mini Rev. Med. Chem., 2005, 5, 409.
16. Narasimhan, B.; Sharma, D.; Kumar, P. Imidazole derivatives as proton pump inhibitor and anticoagulants. Med. Chem. Res., 2012, 21, 269.
17. Pandey, K.B.; Syed, I.R. Anti-oxidative action of resveratrol: Implications for human health. Arabian Journal of Chemistry, 2011, 4, 293-298.
18. Ozkay, Y. Antimicrobial activity and a SAR study of some novel benzimidazole derivatives bearing hydrazone moiety. Eur. J. Med. Chem., 2010, 45, 3293-3298.
19. Sharma, M.C. Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2. International J. Drug delivery, 2010, 2, 265-270.
20. Emami, S.; Foroumadi, A.; Falahati, M.; Lotfali, E.; Rajabalian, S. 2-Hydroxyphenacyl azoles and related azolium derivatives as antifungal agents. Bioorg. Med. Chem. Lett., 2008, 18, 141-146.
21. Ujjinamatada, R.K.; Baier, A.; Borowski, P.; Hosmane, R.S. An analogue of AICAR with dual inhibitory activity against WNV and HCV NTPase/helicase: synthesis and in vitro screening of 4- carbamoyl-5-(4,6-diamino-2,5-dihydro-1,3,5-triazin-2- yl)imidazole-1-beta-D-ribofuranoside. Bioorg. Med. Chem. Lett., 2007, 17, 2285-2288.
22. Shingalapur, R.V.; Hosamani, K.M.; Keri, R.S. Synthesis and evaluation of in vitro anti-microbial and anti-tubercular activity of 2-styryl benzimidazoles. Eur. J. Med. Chem., 2009, 44, 4244-4248.
23. Sharma, D.; Narasimhan, B.; Kumar, P.; Judge, V.; Narang, R.; De Clercq, E.; Balzarini, J. Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives. Eur. J. Med. Chem., 2009, 44, 2347-2353.
24. Jacobs, E.A.; Fuller, A.; Coles, S.J.; Jones, G.A. Synthesis and structure of amido- and imido(pentafluorophenyl)borane zirconocene and hafnocene complexes: N-H and B-H activation. Chemistry, 2012, 18, 8647-8658.
25. Mavrova, A.T.; Anichina, K.K.; Vuchev, D.I.; Tsenov, J.A. Antihelminthic activity of some newly synthesized 5(6)- (un)substituted-1H-benzimidazol-2-ylthioacetylpiperazine derivatives. Eur. J. Med. Chem., 2006, 41, 1412.
26. Haque, R.A.; Iqbal, M.A.; Khadeer Ahamed, M.B. Design, synthesis and structural studies of meta-xylyl linked bisbenzimidazolium salts: potential anticancer agents against 'human colon cancer'. Chem. Cent. J., 2012, 18, 68.
27. Bandyopadhyay, P.; Sathe, M.; Ponmariappan, S. Exploration of in vitro time point quantitative evaluation of newly synthesized benzimidazole and benzothiazole derivatives as potential antibacterial agents. Bioorg. Med. Chem. Lett., 2011, 21, 7306-7309.
28. Arjmand, F.; Mohani, B. Synthesis, antibacterial, antifungal activity and interaction of CT-DNA with a new benzimidazole derived Cu(II) complex. Eur. J. Med. Chem., 2005, 11, 1103-1110.
29. Ansari, K.F. Synthesis, physicochemical properties and antimicrobial activity of some new benzimidazole derivatives. Eur. J. Med. Chem., 2009, 44, 4028-4033.
30. Achar, K.C.S.; Hosamani, K.M. In-vivo analgesic and antiinflammatory activities of newly synthesized benzimidazole derivatives. Eur. J. Med. Chem., 2010, 45, 2048-2054.
31. Camacho, J.; Barazarte, A.; Gamboa, N.; Rodrigues, J. Synthesis and biological evaluation of benzimidazole-5-carbohydrazide derivatives as antimalarial, cytotoxic and antitubercular agents. Bioorg. Med. Chem., 2011, 19, 2023-2029.
32. Zhou, D.; Zhou, P.; Evrard, D.A.; Meagher, K. Studies toward the discovery of the next generation of antidepressants. Part 6: Dual 5- HT1A receptor and serotonin transporter affinity within a class of arylpiperazinyl-cyclohexyl indole derivatives. Bioorg. Med. Chem., 2008, 16, 6707-6723.
33. Demirayak, S.; Kayagil, I.; Yurttas L. Microwave supported synthesis of some novel 1,3-diarylpyrazino[1,2-a]benzimidazole derivatives and investigation of their anticancer activities. Eur. J. Med. Chem., 2011, 46, 411-416.
34. Hwu, J.R.; Singha, R.; Hong, S.C.; Chang, Y.H.; Das, A.R. Synthesis of new benzimidazole-coumarin conjugates as antihepatitis C virus agents. Antiviral Research, 2008, 77, 157-162.
35. Huang, T.L.; Bacchi, C.J.; Kode, N.R.; Zhang, Q. Trypanocidal activity of piperazine-linked bisbenzamidines and bisbenzamidoxime, an orally active prodrug. Inter. J. Antimicro. Agents, 2007, 30, 555-561.
36. Sanders, S.W. Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clinical Therapeutics, 1996, 18, 2-34.
37. Bansal, Y.; Silakari, O. The therapeutic journey of benzimidazoles: a review. Bioorg. Med. Chem., 2012, 20, 6208-6236.
38. Olender, D.; Zwawiak, J.; Lukianchuk, V.; Lesyk, R. Synthesis of some N-substituted nitroimidazole derivatives as potential antioxidant and antifungal agents. Eur. J. Med. Chem., 2009, 44, 645-652.
39. Ansari, K.F.; Lal, C. Synthesis, physicochemical properties and antimicrobial activity of some new benzimidazole derivatives. Eur. J. Med. Chem., 2009, 44, 2294.
40. Ansari, K.F.; Lal, C. Synthesis and evaluation of some new benzimidazole derivatives as potential antimicrobial agents. Eur. J. Med. Chem., 2009, 44, 4028.
41. Gupta, S.P.; Rani, S. Synthesis and antifungal activity of 2- thiohalogenonitrophenyl benzimidazole derivatives. J. Ind. Chem. Soc., 1997, 478.
42. Mane, D.V.; Shinde, D.B.; Thore, S.N.; Shingare, M.S. Synthesis and antimicrobial activities of substituted benzimidazole derivatives. Ind. J. Chem., 1995, 34B, 917.
43. Khalafallh, A.K.; Selim, M.A.; Abu, R.M. Design, synthesis and biological evaluation of of 2-cyanomethyl benzimidazoles. Ind. J. Chem., 1995, 34B, 1066.
44. Mavrova, A.T.; Anichina, K.K.; Vuchev, D.I. Antihelminthic activity of some newly synthesized 5(6)-(un)substituted-1Hbenzimidazol- 2-ylthioacetylpiperazine derivatives. Eur. J. Med. Chem., 2006, 41, 1412.
45. Tamm, I.; Nemes, M.M.; Osterhout, S. On the role of ribonucleic acid in animal virus synthesis. I. Studies with 5,6-dichloro-1-beta- D-ribofuranosylbenzimidazole. J. Exp. Med., 1960, 111, 339.
46. Chodosh, L.A.; Fire, A.; Samuels, M.; Sharp, P.A. 5,6-Dichloro-1- beta-D-ribofuranosylbenzimidazole inhibits transcription elongation by RNA polymerase II in vitro. J. Biol. Chem., 1989, 264, 2250.
47. Townsend, B.L.; Devivar, R.V.; Turk, S.R.; Nassiri, M.R.; Drach, J.C. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo- 1-(beta-D-ribofuranosyl)benzimidazoles. J. Med. Chem., 1996, 38, 4098.
48. Porcari, A.R.; Devivar, R.V.; Kucera, L.S.; Drach, J.C.; Townsend, L.B. Design, synthesis, and antiviral evaluations of 1-(substituted benzyl)-2-substituted-5,6-dichlorobenzimidazoles as nonnucleoside analogues of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole. J. Med. Chem., 1998, 41, 1252.
49. Garuti, L.; Roberti, M.; Gentilomi, G. Synthesis and antiviral assays of some 2-substituted benzimidazole-N-carbamates. Il Farmaco, 2000, 55, 35.
50. Fonseca, T.; Gigante, B.; Marques, M.M.; Gilchrist, T.L.; Clercq, E.D. Synthesis and antiviral evaluation of benzimidazoles, quinoxalines and indoles from dehydroabietic acid. Bioorg. Med. Chem., 2004, 12, 103.
51. Sharma, D.; Narasimhan, B.; Kumar, P. Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives. Eur. J. Med. Chem., 2009, 44, 2347-2353.
52. Starcevic, K.; Kralj, M.; Ester, K.; Sabol, I.; Grce, M.; Pavelic, K.; Zamola, G.K. Synthesis, antiviral and antitumor activity of 2- substituted-5-amidino-benzimidazoles. Bioorg. Med. Chem., 2007, 15, 4419.
53. Vitalea, G.; Cartaa, A.; Lorigaa, M.; Pagliettia, G.; La Collab, P.; Busonerab, B.; Collub, D.; Loddob, R. 2-Arylbenzimidazoles as antiviral and antiproliferative agents. Part 1. Med. Chem., 2008, 4, 605.
54. Vitale, G.; Corona, P.; Loriga, M.; Carta, A.; Pagliettia, G.; Collab, P.L.; Busonera, B.; Marongiu, E.; Collu, D.; Loddo, R. 2- Arylbenzimidazoles as antiviral and antiproliferative agents-Part 2. Med. Chem., 2009, 5, 507.
55. Cheng, J.; Xie, J.T.; Luo, X.J. Synthesis and antiviral activity against Coxsackie virus B3 of some novel benzimidazole derivatives. Bioorg. Med. Chem. Lett., 2005, 15, 267.
56. Li, Y.F.; Wang, G.F.; He, P.L.; Huang, W.G.; Zhu, F.H.; Gao, H.Y.; Tang, W. Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives. J. Med. Chem., 2006, 49, 4790-4794.
57. Barreca, M.L.; Rao, A.; Luca, L.D.; Zappala, M.; Monforte, A.M. Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. J. Med. Chem., 2005, 48, 3433.
58. Barreca, M.L.; Rao, A.; Luca, L.D.; Iraci, N. Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg. Med. Chem. Lett., 2007, 17, 1956.
59. Hirashima, S.; Suzuki, T.; Ishida, T.; Noji, S. Further studies on hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors toward improved replicon cell activities: benzimidazole and structurally related compounds bearing the 2- morpholinophenyl moiety. J. Med. Chem., 2006, 49, 4721.
60. Hirashima, S.; Oka, T.; Ikegashira, K.; Noji, S.; Yamanaka, H. Further studies on hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors toward improved replicon cell activities: benzimidazole and structurally related compounds bearing the 2- morpholinophenyl moiety. Bioorg. Med. Chem. Lett., 2007, 17, 3181.
61. Hwua, J.R.; Singha, R.; Honga, S.C.; Changa, Y.H.; Dasa, A.R.; Vliegen, I.; Clercq, E. D.; Neyts, J. Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents. Antivir. Res., 2008, 77, 157.
62. Beaulieu, P.L.; Dansereau, N.; Duan, J.; Garneau, M. Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series. Bioorg. Med. Chem. Lett., 2010, 20, 1825.
63. Goulet, S.; Poupart, M.A.; Gillard, J.; Poirier, M.; Kukolj, G.; Beaulieu, P.L. Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization. Bioorg.Med. Chem. Lett., 2010, 20, 196.
64. Yu, K.L.; Zhang, Y.; Civiello, R.L.; Kadow, K.F.; Cianci, C.; Krystal, M.; Meanwell, N. A. Fundamental structure-activity relationships associated with a new structural class of respiratory syncytial virus inhibitor. Bioorg. Med. Chem. Lett., 2003, 13, 2141.
65. Yu, K.L.; Zhang, Y.; Civiello, R.L.; Trehan, A.K.; Pearce, B.C.; Yin, Z. Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives. Bioorg. Med. Chem. Lett., 2004, 14, 1133.
66. Yu, K.L.; Wang, X.A.; Civiello, R.L.; Trehan, A.K.; Pearce, B.C.; Yin, Z. Respiratory syncytial virus fusion inhibitors. Part 3: Watersoluble benzimidazol-2-one derivatives with antiviral activity in vivo. Bioorg. Med. Chem. Lett., 2006, 16, 1115.
67. Yu, K.L.; Sin, N.; Civiello, R.L.; Wang, X.A.; Combrink, K.D. Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg. Med. Chem. Lett., 2007, 17, 895.
68. Wang, X.A.; Cianci, C.W.; Yu, K.L.; Combrink, K.D. Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity. Bioorg. Med. Chem. Lett., 2007, 17, 4592.
69. Keith, D.; Combrink, H.; Gulgeze, B.; Thuring, J.W.; Yu, K.L. Respiratory syncytial virus fusion inhibitors. Part 6: an examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety. Bioorg. Med. Chem. Lett., 2007, 17, 4784.
70. Carcanague, D.; Shue, Y.K.; Wuonola, M.A. Novel structures derived from 2-[[(2-pyridyl) methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 2. J. Med. Chem., 2002, 45, 4300-4309.
71. Lindberg, P.; Nordberg, P.; Alminger, T.; Bradstrom, A.; Wallmark, B. The mechanism of action of the gastric acid secretion inhibitor omeprazole. J. Med. Chem., 1986, 29, 1327-1329.
72. Grassi, J.I.; Bruno, M.; Thomas, G. BAY P 1455, a thiazolylaminobenzimidazole derivative with gastroprotective properties in the rat. Eur. J. Pharmacology, 1991, 195, 251-259.
73. Kosaka, N.; Tanaka, H.; Tomaru, A.; Ishii, A.; Shuto, K. Effects of KW-5805, a new antiulcer agent, on experimental gastric and duodenal ulcers, gastric mucosal lesions by necrotizing agents and gastric acid secretion. Jpn. J. Pharmacol., 1994, 65, 305-312.
74. Kohl, B.; Sturm, E.; Blifinger, J.S.; Alexander, W.; Kruger, S.V. (H+,K+)- ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate. J. Med. Chem., 1992, 35, 1049-1057.
75. Yamada, S.; Goto, T.; Shimanuki, E.; Narita, S. Synthesis and antiulcer activities of novel 2-[(6,7,8,9-tetrahydro-5Hcyclohepta[ b]pyridin-9-yl)sulfinyl]-1H- benzimidazole analogues. Chem. Pharm. Bull., 1994, 42, 718-20.
76. Yamada S, Goto T, Yuasa S, Yamaguchi T, Kogi K. Synthesis of stable solvates of monosodium 2-[R*s,9S*)-(4-methoxy-6,7,8,9- tetrahydro-5H-cyclohepta[b]pyridin-9-yl)sulfinyl]-1Hbenzimidazole. Yakugaku Zasshi, 1996, 116, 657-670.
77. Hiroshi, S.; Koji, T.; Akito, K.; Yasuhiro, I.; Isami, K.; Asyoshi, K.; Mikiko, K.; Makota, S. Basicity of ring nitrogen of pyridine and irreversibility of compound with enzymes as ring substituent Chem. Pharm. Bull., 1995, 43,166-168.
78. Ung, K.S.; Yeon, K.D.; Ju, C.G.; Kol, H.S.; Jun, P.S.; Hoon, N.S.; Suk, L.Y. World Patent, 1995, No. 9523140.
79. Elof, B.A.; Kerstin, S.I.; Hijelte, T.; Inaera, L. World Patent, 1995, No. 9515962.
80. Jain, K.S.; Shah, A.K.; Bariwal, S.M.; Shelke, A.P.; Kale, J.R.; Jagtap, A.V. Recent advances in proton pump inhibitors and management of acid-peptic disorders. Bioorg. Med. Chem., 2007, 15, 1181-1205.
81. Kaun, Y.E.; Kwon, C.J.; Yun, C.S.; Kyu, K.S. World Patent, 1997, No. 9700875.
82. Yong, Y.H.; Jong, C.K.; Mansik, C.; Gyu, K.S.; Soo, C.W. World Patent, 1997, No.9703077.
83. Nicole, B.; Timur, G.; Jean, L.; Michele, L.; Marie, T.J. Eur. Patent, 1990, No. 385850.
84. Uchida, M.; Chihiro, M.; Morita, S.; Yamashita, H. Synthesis and antiulcer activity of 4-substituted 8-[(2- benzimidazolyl)sulfinylmethyl]-1,2,3,4-tetrahydroquinoli nes and related compounds. Chem.Pharm.Bull., 1990, 38, 1575-1586.
85. Kovalev, G.V.; Spasor, A.A.; Bakumov, P.A.; Reshetov, M.E.; Anisimova, V.A. Design, synthesis and biological evaluation of 9- (diethyl amino ethylene)-2-phenyl imidazo [1,2-a] benzimidazoles. Himiko-Farmatsevticheskii Zhurnal, 1990, 24, 127-30.
86. Sih, J.C.; Im, W.B.; Robert, A. Studies on (H(+)-K+)-ATPase inhibitors of gastric acid secretion. Prodrugs of 2-[(2- pyridinylmethyl)sulfinyl]benzimidazole proton-pump inhibitors. J. Med. Chem., 1991, 34, 1049-1062.
87. Grassi, J.I.; Bruno, M.; Thomas, G. BAY P 1455, a thiazolylaminobenzimidazole derivative with gastroprotective properties in the rat. Eur. J. Pharmacology, 1991, 195, 251-259.
88. Kiyoaki, K.; Tamaka, T.; Hiroko, O.; Fumiya, H.; Yasukatsu, Y.; Fukio, K. Eur Patent, 1991, No.457331.
89. Lindberg, A.E.; Lennart, P. World Patent, 1991, No. 9119712.
90. Takashi, S.; Nobuhiro, I. Eur Patent, 1992, No.481764.
91. Lohray, B.B.; Lohray, V.B.; Kommireddi, G.P. US Patent, 2000, No. 6051570 (2000).
92. Keiji, K.; Fumihiko, S. World Patent, 2002, No. 2002030920.
93. Carcanague, D.; Shue, Y.K.; Wuonola, M.A. Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 2. J. Med. Chem., 2002, 45, 4300-4309.
94. Michael, G.; George, S.; Moo, S.J. US Patent, 2003, No.6559167.
95. Reddy, S.G.; Hegde, P.P.; Ranjan, P.C. Synthesis and biological evaluation of N-(1-(cyclohex-3-enylmethyl)piperidin-4-yl)-6- ethoxy-2-propyl-1H-benzo[d]imidazole-5-carboxamide derivatives. Het. Comm., 2005, 11, 23-28.
96. Kohl, R.; Ganguly, S.; Patil, A.; Surana, S. Synthesis and antiulcer activity of 2-((3-methyl-4-(3-(4-methyl-4H-1, 2, 4-triazol-3-ylthio) propylthio) pyridin-2-yl) methylthio)-1H-benzo[d]imidazole. Rasayan J. Chem., 2008, 1, 447-460.
97. Medzhitov, R. Inflammation 2010: new adventures of an old flame. Cell, 2010, 140, 771.
98. Grivennikov, S.; Greten, F. R.; Karin, M. Immunity, inflammation, and cancer. Cell, 2010, 140, 883.
99. Nathan, C. Points of control in inflammation. Nature, 2002, 420, 846.
100. Cronstein, B.N.; Weissmann, G. Targets for antiinflammatory drugs. Annu. Rev. Pharmacol. Toxicol., 1995, 35, 449.
101. Feghali, C.A.; Wright, T.M. Cytokines in acute and chronic inflammation. Frontiers Biosci., 1997, 2, 12.
102. Bhagwat, S.S. Kinase inhibitors for the treatment of inflammatory and autoimmune disorders. Purinergic Signal, 2009, 5, 107.
103. Dinarello, C.A. Anti-inflammatory Agents: Present and Future. Cell, 2010, 140, 935.
104. Gonzalez-Rey, E.; Delgado, M. Role of vasoactive intestinal peptide in inflammation and autoimmunity. Curr. Opin. Investig. Drugs, 2005, 6, 1116-1123.
105. Delgado, M.; Munoz-Elias, E.J.; Gomaiz, R.P., Ganea, D. Vasoactive intestinal peptide and pituitary adenylate cyclaseactivating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J. Immunol., 1999, 162, 1707-1716.
106. Delgado, M.; Reduta, M.; Sharma, V.; Ganea, D. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. J. Leukoc. Biol., 2004, 75, 1122-1130.
107. Vally, M.; Seenu, S.; Pillarisetti, S. Emerging peptide therapeutics for inflammatory diseases. Curr. Pharm. Biotechnol., 2006, 7, 241-246.
108. Achar, K.C.S.; Hosamani, K.M.; Seetharamareddy, H.R. In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives. Eur. J. Med. Chem., 2010, 45, 2048-2054.
109. Abu-Hashem, A.; Gouda, M; Badria F.A. Synthesis of some new pyrimido[2',1':2,3]thiazolo[4,5-b]quinoxaline derivatives as antiinflammatory and analgesic agents. Eur. J. Med. Chem., 2010, 5, 1976-1981.
110. Taniguchi, K.; Shigenaga, S.; Ogahara, T.; Fujitsu, T.; Matsuo, M. Synthesis and antiinflammatory and analgesic properties of 2-amino- 1H-benzimidazole and 1,2-dihydro-2-iminocycloheptimidazole derivatives. Chem. Pharma. Bull., 1993, 41, 301-309.
111. Mohan, R.R.; Agarwal, C.; Agarwal, R.; Misra, V.S. CNS, anthelmintic and antiinflammatory activities of some 1-[2/3-(2-phenyl benzimidazole)]2-methyl/phenyl-4-(3,4-disubstituted benzylidene)5- oxo-imidazoles. Pharmacol. Res. Commun., 1984, 16, 321.
112. Gaba, M.; Sing, D.; Singh, S.; Sharma, V.; Gaba, P. Synthesis and pharmacological evaluation of novel 5-substituted-1-(phenylsulfonyl)- 2-methylbenzimidazole derivatives as anti-inflammatory and analgesic agents. Eur. J. Med. Chem., 2010, 45, 2245.
113. Tsukamoto, G.; Yoshino, K.; Kohno, T.; Ohtaka, H.; Kagaya, H.; Ito, K. Synthesis and antiinflammatory activity of some 2-(substitutedpyridinyl) benzimidazoles. J. Med. Chem., 1980, 23, 734.
114. Ito, K.; Kagaya, H.; Fukuda, T.; Yoshino, K.; Nose, T. Pharmacological studies of a new non-steroidal antiinflammatory drug: 2-(5- ethylpyridin-2-yl)benzimidazole (KB-1043). Arzneimittel-forschung, 1982, 32, 49.
115. Ito, K.; Kagaya, H.; Satoh, I.; Tsukamoto, G.; Nose, T. The studies of the mechanism of antiinflammatory action of 2-(5-ethylpyridin-2- yl)benzimidazole (KB-1043). Arzneimittel-forschung, 1982, 32, 117.
116. Hosamani, K.M.; Seetharamareddy, H.R. In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives. Eur. J. Med. Chem., 2010, 45, 2048.
117. El-Nezhawy, A.O.H.; Gaballah, S.T.; Radwan, M.A.A.; Baiuomy, A.R.; Abdel Salam, A.M.E. Structure-based design of benzimidazole sugar conjugates: synthesis, SAR and in vivo antiinflammatory and analgesic activities. Med. Chem., 2009, 5, 558.
118. Dunwel, D.W.; Evans, D.; Smith, C.E.; Williamson, W.R.N. Synthesis and antiinflammatory activity of some-2-substituted alpha-methyl-5-benzimidazoleacetic acids. J. Med. Chem., 1975, 18, 692.
119. Carson, J.R.; Wong, S. 5-Benzoyl-1-methylpyrrole-2-acetic acids as antiinflammatory agents. 2. The 4-methyl compounds. J. Med. Chem., 1973, 16, 172-174.
120. Terzioglu, N.; Van rijn, R.M.; Bakker, R.A.; De Esch, I.J.P.; Leurs, R. Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists. Bioorg. Med. Chem. Lett., 2004, 14, 5251.
121. Coruzzi, G.; Adami, M.; Guaita, E.; De Esch, I.J.P.; Leurs, R. Antiinflammatory and antinociceptive effects of the selective histamine H4-receptor antagonists JNJ7777120 and VUF6002 in a rat model of carrageenan-induced acute inflammation. Eur. J. Pharmacol., 2007, 563, 240.
122. Shih, C.M.; Cheng, S.N.; Wong, C.S.; Kuo, Y.L.; Chou, T.C. Antiinflammatory and antihyperalgesic activity of C-phycocyanin. Anesth. Analg., 2009, 108, 1303-1310.
123. Schulz, W.G.; Islam, I. Pyrrolo[1,2-a]benzimidazole-based quinones and iminoquinones. The role of the 3-substituent on cytotoxicity. J. Med. Chem., 1995, 38, 109.
124. Sharma P.S.; Sharma, R.; Tyagi, R. Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. Curr. Cancer Drug Targets, 2008, 8, 53.
125. Finlay M.R.V.; Acton, D.G.; Andrews, D.M. Imidazole piperazines: SAR and development of a potent class of cyclindependent kinase inhibitors with a novel binding mode. Bioorg. Med. Chem. Lett., 2008, 18, 4442.
126. Jones C.D.; Andrews, D.M.; Barker, A.J.; Bladesa, K.; Daunt, P. The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing. Bioorg. Med. Chem. Lett., 2008, 18, 6369-6373.
127. Ling, V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol., 1997, 40, S3.
128. Kaye, S. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr. Opin. Oncol., 1998,10, S15.
129. Tian, Q.; Zhang, J.; Chan, E.; Duan, W.; Zhou, S. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Drug Dev. Res., 2005, 64, 1.
130. Leslie, E.; Deeley, R; Cole, S. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol., 2005, 204-216.
131. Polgar, O.; Bates, S. ABC transporters in the balance: is there a role in multidrug resistance? Biochem. Soc. Trans., 2005, 33, 241.
132. Kim, C.; Gollapudi, S.; Lee, T.; Gupta, S. Altered expression of the genes regulating apoptosis in multidrug resistant human myeloid leukemia cell lines overexpressing MDR1 or MRP gene. Int. J. Oncol., 1997, 11, 945.
133. Ferlini, C.; Raspaglio, G.; Mozzeti, S.; Cicchillitti, L.; Fillippetti, F.; Gallo, D.; Fattorusso, C.; Campiani, G.; Scambia, G. The secotaxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res., 2005, 2397.
134. Wessel, I.; Jensen, P.; Falck, J.; Mirski, S.; Cole, S.; Sehested, M. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. Cancer Res., 1997, 57, 4451.
135. Hu, Y.; Stephen, A.; Cao, J.; Tanzer, L.; Slapak, C. A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells. Int. J. Cancer, 2002, 97, 149-156.
136. Ferguson, R.; Roisean, E.; Jackson, S.; Stanley, A. Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. Int. J. Cancer, 2005, 115, 155.
137. Robert, J.; Jarry, C. Multidrug resistance reversal agents. J. Med. Chem., 2003, 46, 4805.
138. Lin N.H.; Wang, L.; Wang, X.; Wang, G.T. Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1Himidazole as novel farnesyltransferase inhibitor. Bioorg. Med. Chem. Lett., 2004, 14, 5057-5062.
139. Hadfield, J.A.; Ducki, S.; Hirst, N.; McGown, A.T. Tubulin and microtubules as targets for anticancer drugs. Prog. Cell Cycle Res., 2003, 5, 309.
140. Kostakis, I.K.; Pouli, N.; Marakos, P.; Kousidou, O.C.; Roussidis, A. Design, synthesis and cell growth inhibitory activity of a series of novel aminosubstituted xantheno[1,2-d]imidazoles in breast cancer cells. Bioorg. Med. Chem., 2008, 16, 3445-3455.
141. Chung, K.H.; Hong, S.Y.; You, H.J.; Parka, R.E.; Ryua, C.K. Synthesis and biological evaluation of 5-arylamino-1Hbenzo[ d]imidazole-4,7-diones as inhibitor of endothelial cell proliferation. Bioorg. Med. Chem., 2006, 14, 5795-5801.
142. Gellis, A.; Kovacic, H.; Boufatah, N.; Vanelle, P. Synthesis and cytotoxicity evaluation of some benzimidazole-4,7-diones as bioreductive anticancer agents. Eur. J. Med. Chem., 2008, 43, 1858.
143. Sondhi, S.M.; Rani, M.; Sigh, J.; Roy, P.; Agrawal, S.K.; Saxena, A.K. Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives. Bioorg. Med. Chem. Lett., 2010, 20, 2306.
144. Demirayak, S.; Mohsen, U.A.; Karaburun, A.C. Synthesis and anticancer and anti-HIV testing of some pyrazino[1,2- a]benzimidazole derivatives. Eur. J. Med. Chem., 2002, 37, 255.
145. Refaat, H.M. Synthesis and anticancer activity of some novel 2- substituted benzimidazole derivatives. Eur. J. Med. Chem., 2010, 45, 2949.
146. Shaharyar, M.; Abdullah, M.M.; Bakht, M.A.; Majeed, M. Pyrazoline bearing benzimidazoles: search for anticancer agent. Eur. J. Med. Chem., 2010, 45, 114.
147. Thimmegowda, N.R.; Swamy, S.N.; Kumar, C.S.A. Synthesis, characterization and evaluation of benzimidazole derivative and its precursors as inhibitors of MDA-MB-231 human breast cancer cell proliferation. Bioorg. Med. Chem. Lett., 2008, 18, 432.
148. Özkay, Y.; Iskar, I.; Incesu, Z.; Akalin G.E. Synthesis of 2- substituted-N-[4-(1-methyl-4,5-diphenyl-1H-imidazole-2- yl)phenyl]acetamide derivatives and evaluation of their anticancer activity. Eur. J. Med. Chem., 2010, 45, 3320-3328.
149. Congiu, C.; Cocco, M.T.; Onnis, V. Design, synthesis, and in vitro antitumor activity of new 1,4-diarylimidazole-2-ones and their 2- thione analogues. Bioorg. Med. Chem. Lett., 2008, 18, 989-993.
150. Schulz, W.G.; Islam, I.; Skibo, E.B. Pyrrolo[1,2-a]benzimidazolebased quinones and iminoquinones. The role of the 3-substituent on cytotoxicity. J. Med. Chem., 1995, 38, 109.
151. Islam, I.; Skibo, E.B.; Dorr, R.T.; Alberts, D.S. Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents. J. Med. Chem., 1991, 34, 2954.
152. Skibo, E.B.; Schulz, W.G. Pyrrolo[1,2-a]benzimidazole-based aziridinyl quinones. A new class of DNA cleaving agent exhibiting G and A base specificity. J. Med. Chem., 1993, 36, 3050.
153. Skibo, E.B.; Islam, I.; Heileman, M.J.; Schulz, W.G. Structureactivity studies of benzimidazole-based DNA-cleaving agents. Comparison of benzimidazole, pyrrolobenzimidazole, and tetrahydropyridobenzimidazole analogues. J. Med. Chem., 1994, 37, 78.
154. Kumar, R.; Lown, J.W. Recent developments in novel pyrrolo[2,1- c][1,4]benzodiazepine conjugates: synthesis and biological evaluation. Mini. Rev. Med. Chem., 2003, 3, 323-339.
155. Boruah, R.C.; Skibo, E.B. A comparison of the cytotoxic and physical properties of aziridinyl quinone derivatives based on the pyrrolo[1,2-a]benzimidazole and pyrrolo[1,2-a]indole ring systems. J. Med. Chem., 1994, 37, 1625.
156. El-Naem, Sh.I.; El-Nazhawy, A.O.; El-Diwani, H.I.; Abdel Hamid, A.O. Synthesis of 5-substituted 2-methylbenzimidazoles with anticancer activity. Arch. Der Pharm., 2003, 336, 7.
157. Ramla, M.M.; Omar, M.A.; Tokuda, H.; El-Diwani, H.I. Synthesis and inhibitory activity of new benzimidazole derivatives against Burkitt's lymphoma promotion. Bioorg. Med. Chem., 2007, 15, 6489.
158. Ni, Z.J.; Barsanti, P.; Brammeier, N.; Diebes, A. 4- (Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK- 1 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 3121.
159. Neff, D.K.; Dutra, A.L.; Blevitt, J.M.; Axe, F.U. 2-Aryl benzimidazoles featuring alkyl-linked pendant alcohols and amines as inhibitors of checkpoint kinase Chk2. Bioorg. Med. Chem. Lett., 2007, 17, 6467.
160. Zhong, M.; Bui, M.; Shen, W.; Baskaran, S.; Allen, D.A. 2- Aminobenzimidazoles as potent Aurora kinase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 5158.
161. Abdel-Mohsen, H.T.; Ragab, F.A.F.; Ramla, M.M.; El Diwani, H.I. Novel benzimidazole-pyrimidine conjugates as potent antitumor agents. Eur. J. Med. Chem., 2010, 45, 2336.
162. Shaharyar, M.; Abdullah, M.M.; Bakht, M.A.; Majeed, J. Pyrazoline bearing benzimidazoles: search for anticancer agent. Eur. J. Med. Chem., 2010, 45, 114.
163. Luo, Y.; Xiao, F.; Qian, S.; Lu, W.; Yang, B. Synthesis and in vitro cytotoxic evaluation of some thiazolylbenzimidazole derivatives. Eur. J. Med. Chem., 2011, 46, 417.
164. Chen, A.; Yu, C.; Gatto, B.; Liu, L.F. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. U.S.A., 1993, 90, 8131.
165. Chen, A.Y.; Yu, C.; Bodley, A.L.; Peng, L.F.; Liu, L.F. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res., 1993, 53, 1332.
166. Kraut, E.; Fleming, T.; Segal, M.; Neidhart, J.; Behrens, B.C.; MacDonald, J. Phase II study of pibenzimol in pancreatic cancer. A Southwest Oncology Group study. Invest. New Drugs, 1991, 9, 95.
167. Tolner, B.; Hartly, J.A.; Hochhauser, D. Transcriptional regulation of topoisomerase II alpha at confluence and pharmacological modulation of expression by bis-benzimidazole drugs. Mol. Pharamcol., 2001, 59, 699.
168. Beerman, T.A.; McHugh, M.M.; Sigmund, R.; Lown, J.W.; Rao, K.E.; Bathini, Y. Effects of analogs of the DNA minor groove binder Hoechst 33258 on topoisomerase II and I mediated activities. Biochim. Biophys. Acta., 1992, 53, 1131.
169. Ueki, M.; Ueno, K.; Miyadoh, S.; Abe, K.; Shibata, K.; Taniguchi, M.; Oi, S.J. UK-1, a novel cytotoxic metabolite from Streptomyces sp. 517-02. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties. J. Antibiot., 1993, 46, 1089.
170. Sato, S.; Kajiura, T.; Noguchi, M.; Takehana, K.; Kobayasho, T.; Tsuji, T.J. AJI9561, a new cytotoxic benzoxazole derivative produced by Streptomyces sp. J. Antibiot., 2001, 54, 102.
171. Ueki, M.; Shibata, K.; Taniguchi, M. UK-1, a novel cytotoxic metabolite from Streptomyces sp. 517-02. IV. Antifungal action of methyl UK-1. J. Antibiot., 1998, 51, 883.
172. Ueki, M.; Taniguchi, M. UK-3A, a novel antifungal antibiotic from Streptomyces sp. 517-02: fermentation, isolation, structural elucidation and biological properties. J. Antibiot., 1997, 50, 788.
173. Huang, S.T.; Hseib, I.J. Synthesis and anticancer evaluation of bis(benzimidazoles), bis(benzoxazoles), and benzothiazoles. Bioorg. Med. Chem., 2006, 14, 6106.
174. Styskala, J.; Styskalova, L.; Slouka, J.; Hajduch, M. Synthesis of 2- aryl-4-(benzimidazol-2-yl)-1,2-dihydro[1,2,4]triazino-[4,5- a]benzimidazol-1-one derivatives with preferential cytotoxicity against carcinoma cell lines. Eur. J. Med. Chem., 2008, 43, 449.
175. Stolic, I.; Miškovic, K.; Magdaleno, A.; Silber, A.M.; Piantanida, I. Effect of 3,4-ethylenedioxy-extension of thiophene core on the DNA/RNA binding properties and biological activity of bisbenzimidazole amidines. Bioorg. Med. Chem., 2009, 17, 2544.
176. Yang, Y.H.; Cheng, M.S.; Wang, Q.H.; Nie, H.; Liao, N.; Wang, J.; Chen, H. Design, synthesis, and anti-tumor evaluation of novel symmetrical bis-benzimidazoles. Eur. J. Med. Chem., 2009, 44, 1808.
177. Singh, M.; Tandon, V. Synthesis and biological activity of novel inhibitors of topoisomerase I: 2-aryl-substituted 2-bis-1Hbenzimidazoles. Eur. J. Med. Chem., 2011, 46, 659.
178. Mavrova, A.T.; Vuchev, D.; Anichina, K.; Vassilev, N. Synthesis, antitrichinnellosis and antiprotozoal activity of some novel thieno[2,3-d]pyrimidin-4(3H)-ones containing benzimidazole ring. Eur. J. Med. Chem., 2010, 45, 5856.
179. Gomez, H.T.; Nunez, E.H.; Rivera, I.L.; Alvarez, J.G.; Rivera, R.C. Design, synthesis and in vitro antiprotozoal activity of benzimidazole-pentamidine hybrids. Bioorg. Med. Chem. Lett., 2008, 18, 3147.
180. Ismail, M.A.; Brun, R.; Wenzler, T.; Tanious, F.A.; Wilson, W.D.; Boykin, D.W. Dicationic biphenyl benzimidazole derivatives as antiprotozoal agents. Bioorg. Med. Chem., 2004, 12, 5405.
181. Kopanska, K.; Najda, A.; Zebrowska, J.; Chomicz, L.; Piekarczyk, J.; Myjak, P.; Bretner, M. Synthesis and activity of 1Hbenzimidazole and 1H-benzotriazole derivatives as inhibitors of Acanthamoeba castellanii. Bioorg. Med. Chem., 2004, 12, 2617.
182. Vazquez, G.N.; Cedillo, R.; Campos, A.H.; Yepez, L.; Luis, F.H.; Valdez, J.; Morales, R.; Cortes, R.; Hernandez, M.; Castillo, R. Synthesis and antiparasitic activity of 2-(trifluoromethyl)- benzimidazole derivatives. Bioorg. Med. Chem. Lett., 2001, 11, 187.
183. Vazquez, G.N.; Vilehis, M.M.R.; Mulia, L.Y.; Melendez, V.; Gerena, L.; Campos, A.H.; Castillo, R.; Luis, F.H. Synthesis and antiprotozoal activity of some 2-(trifluoromethyl)-1Hbenzimidazole bioisosteres. Eur. J. Med. Chem., 2006, 41, 135.
184. Kazimierczuk, Z.; Upcroft, J.A.; Upcroft, P.; Gorska, A.; Starosciak, B.; Laudy, A. Synthesis, antiprotozoal and antibacterial activity of nitro- and halogeno-substituted benzimidazole derivatives. Acta Biochim. Pol., 2002, 49, 185.
185. Tremblay, M.; Bonneau, P.; Bousquet, Y.; DeRoy, P.; Duan, J. Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5- (5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold. Bioorg. Med. Chem. Lett., 2012, 22, 7512-7517.
186. Abonia, R.; Cortés, E.; Insuasty, B.; Quiroga, J.; Nogueras, M.; Cobo, J. Synthesis of novel 1,2,5-trisubstituted benzimidazoles as potential antitumor agents. Eur. J. Med. Chem., 2011, 46, 4062-4070.
187. Shingalapur, R.V.; Hosamani, K.M.; Keri, R.S. Synthesis and evaluation of in vitro anti-microbial and anti-tubercular activity of 2-styryl benzimidazoles. Eur. J. Med. Chem., 2009, 44, 4244-4248.
188. Gupta, P.; Hameed, S.; Jain, R. Ring-substituted imidazoles as a new class of anti-tuberculosis agents. Eur. J. Med. Chem., 2004, 39, 805-814.
189. Jyoti, P.; Vinod, T.K.; Shyam, V.S.; Vinita, C.; Bhatnagar, S.; Sinha, S.; Gaikwad, A.N.; Tripathi, R.P. Synthesis and antitubercular screening of imidazole derivatives. Eur. J. Med. Chem., 2009, 44, 3350-3355.
190. Ghanbarpour, A.; Hadizadeh, F.; Piri, F.; Rashidi-Ranjbar, P. Synthesis, conformational analysis and antidepressant activity of moclobemide new analogues. Pharm. Acta. Helv., 1997, 72, 119-122.
191. Bhandari, K.; Srinivas, N.; Marrapu, V.K.; Verma, A.; Srivastava, S.; Gupta, S. Synthesis of substituted aryloxy alkyl and aryloxy aryl alkyl imidazoles as antileishmanial agents. Bioorg. Med. Chem. Lett., 2010, 20, 291-293.
192. Naik, P.; Murumkar, P.; Giridhar, R.; Yadav, M.R. Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective. Bioorg. Med. Chem., 2010, 18, 8418.
193. Kubo, K.; Inada, Y.; Kohara, Y.; Sugiura, Y.; Ojima, M.; Itoh, K.; Furukawa, Y.; Nishikawa, K.; Nakat, T. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles. J. Med. Chem., 1993, 36, 1772.
194. Shah, D.I.; Sharma, M.; Bansal, Y.; Bansal, G.; Singh, M. Angiotensin II--AT1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives. Eur. J. Med. Chem., 2007, 20, 1-5.
195. Romagnoli, R.; Baraldi, P.G.; Carrion, M.D. Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[(4- arylpiperazin-1-yl)methyl]-5-substituted-thiophenes. effect of the 5-modification on allosteric enhancer activity at the A1 adenosine receptor. J. Med. Chem., 2012, 13, 7719-7735.
196. Kubo, K.; Kohara, Y.; Imamiya, Y.; Sugiura, Y.; Inada, Y.; Furukawa, Y.; Nishikawa, K.; Naka, T. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids. J. Med. Chem., 1993, 36, 2182.
197. Wong, P.C.; Hart, S.D.; Chiu, A.T.; Herblin, W.F.; Carini, D.J.; Smith, R.D. Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonist. J. Pharmacol. Exp. Ther., 1991, 259, 961-870.
198. Ojima, M.; Inada, Y.; Shibouta, Y.; Wada, T.; Sanada, T.; Kubo, K.; Nishikawa, K. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur. J. Pharmacol., 1997, 319, 137.
199. Shibouta, Y.; Inada, Y. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'- (1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7- carboxylic acid (CV-11974), and its prodrug, (+/-)-1- (cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV- 116). J. Pharmacol. Exp. Ther., 1993, 266, 114.
200. Ogihara, T.; Nagano, M.; Higaki, J.; Kohara, K.; Mikami, H. Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects. J. Cardiovasc. Pharmacol., 1995, 26, 490.
201. Kubo, K.; Kohara, Y.; Yoshimura, Y.; Inada, Y.; Shibouta, Y.; Furukawa, Y.; Kato, T.; Nishikawa, K.; Naka, T. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids. J. Med. Chem., 1993, 36, 2343.
202. Yamaki, F.; Arai, T.; Aoyama, M. Angiotensin AT1-Receptor Blockers Enhance Cardiac Responses to Parasympathetic Nerve Stimulation via Presynaptic AT1 Receptors in Pithed Rats. J. Pharmacol. Sci., 2013, 122, 28-33.
203. Inada, Y.; Wada, T.; Shibouta, Y.; Ojima, M. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy) ethyl 2- ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1Hbenzimidazole- 7-carboxylate (TCV-116), in various hypertensive rats. J. Pharmacol. Exp. Ther., 1994, 268, 1540.
204. Timmermans, P.B.; Carini, D.J.; Chiu, A.T.; Duncia, J.V. Angiotensin II receptor antagonists. From discovery to antihypertensive drugs. Hypertension, 1991, 18, 136-142.
205. Thomas, A.P.; Allott, C.P.; Gibson, K.H.; Major, J.S.; Masek, B.B. New nonpeptide angiotensin II receptor antagonists. 1. Synthesis, biological properties, and structure-activity relationships of 2-alkyl benzimidazole derivatives. J. Med. Chem., 1992, 35, 877.
206. Palkowitz, A.D.; Steinberg, M.I.; Zimmerman, K.M.; Thrasher, K.J.; Hauser, K.L.; Boyd, D.B. Chiral recognition of the angiotensin II (AT1) receptor by a highly potent phenoxyproline octanoamide. Bioorg. Med. Chem. Lett., 1994, 4, 51-56.
207. Xu, J.; Yang, J.; Ran, Q.; Wang, L. Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates. Bioorg. Med. Chem. Lett., 2008, 18, 4714-4744.
208. Wienen, W.; Hauel, N.; Van Meel, J.C.A.; Narr, B.; Ries, U.J.; Entzeroth, M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br. J. Pharmacol., 1993, 110, 245.
209. Israili, Z.H. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J. Hum. Hypertens., 2000, 1, 73-86.
210. Bali, A.; Bansal, Y.; Sugumaran, Y. Design, synthesis, and evaluation of novelly substituted benzimidazole compounds as angiotensin II receptor antagonists. Bioorg. Med. Chem. Lett., 2005, 15, 3962.
211. Shah, D.I.; Sharma, M.; Bansal, Y.; Bansal, G.; Singh, M. Angiotensin II-AT1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives. Eur. J. Med. Chem., 2008, 43, 1808.
212. Kaur, N.; Kaur, A.; Bansal, Y.; Shah, D.I.; Bansal, G.; Singh, M. Design, synthesis, and evaluation of 5-sulfamoyl benzimidazole derivatives as novel angiotensin II receptor antagonists. Bioorg. Med. Chem., 2008, 16, 10210.
213. Izuhara, Y.; Sada, T.; Yanagisawa, H.; Koike, H.; Ohtomo, S. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 1767-1773.
214. Yanik, M.; Feig, D.I. Serum urate: a biomarker or treatment target in pediatric hypertension? Curr. Opin. Cardiol., 2013, 28, 433-438.
215. Cevik, C.; Işeri, S.O. The effect of acupuncture on high blood pressure of patients using antihypertensive drugs. Acupunct. Electrother. Res., 2013, 38, 1-15.
216. Sheffler, D.J.; Sevel, C.; Le, U.; Lovell, K.M.; Tarr, J.C. Further exploration of M1 allosteric agonists: subtle structural changes abolish M1 allosteric agonism and result in pan-mAChR orthosteric antagonism. Bioorg. Med. Chem. Lett., 2013, 23, 223-227.
217. Sharma, M.C.; Kohli, D.V.; Sharma, S. Design and synthesis of tetrazolylbiphenyl or carboxylbiphenyl substituted benzimidazoles. Int. J. Adv. Pharm. Sci., 2010, 1, 249.
218. Sharma, M.C.; Kohli, D.V.; Sharma, S. Benzimidazole derivatives and potent antihypertensive and vasodilator agents. Int. J. Drug Delivery, 2010, 2, 228.
219. Sharma, M.C.; Kohli, D.V.; Sharma, S. Recent advances in antihypertensive agents with vasodilator activity. Int. J. Drug Delivery, 2010, 2, 265.
220. Sharma, S.; Sharma, M.C.; Kohli, D.V. S Synthesis and vasodilator activity of sartans with tetrazolylbiphenyl or carboxylbiphenyl substituted benzimidazoles. J. Optoelectro. Biomed. Mat., 2010, 2, 203.
221. Estrada-Soto, S.; Villalobos-Molina, R.; Aguirre-Crespo, F.; Vergara- Galicia, J.; Moreno-Díaz, H. Relaxant activity of 2-(substituted phenyl)-1H-benzimidazoles on isolated rat aortic rings: design and synthesis of 5-nitro derivatives. Life Sci., 2006, 79, 430-435.
222. Dorsch, D.; Cezanne, B.; Mederski, W.; Tsaklakidis, C.; Gleitz, J.; Barnes, C.U.S. Patent. US 7566789B2, 2009.
223. Naka T. Angiotensin II receptor antagonist activities and mode of action of benzimidazole-7-carboxylic acid derivatives. Nihon Rinsho., 1993, 51, 1575-1579.
224. Wu, J.; Wang, Q.; Guo, J.; Hu, Z.; Yin, Z.; Xu, J.; Wu, X. Characterization of angiotensin II antagonism displayed by Ib, a novel nonpeptide angiotensin AT(1) receptor antagonist. Eur. J. Pharmacol., 2008, 589, 220-224.
225. Cole, E.R.; Crank, G.; Salam-Sheikh, A. Antioxidant properties of benzimidazoles. J. Agr. Food Chem., 1974, 22, 918.
226. Kus, C.; Ayhan-Kilcigil, G.; Eke, B.C.; Iscan, M. Synthesis and antioxidant properties of some novel benzimidazole derivatives on lipid peroxidation in the rat liver. Arch. Pharm. Res., 2004, 27, 156.
227. Kus, C.; Ayhan-Kilcigil, G.; Ozbey, S.; Betu, F.; Kaynak, I.; Kaya, M.; Coban, T.; Can-Eke, B. Synthesis and antioxidant properties of novel N-methyl-1,3,4-thiadiazol-2-amine and 4-methyl-2H-1,2,4- triazole-3(4H)-thione derivatives of benzimidazole class. Bioorg. Med. Chem., 2008, 16, 4294.
228. Prashanth, M.K.; Revanasiddappa, H.D.; Lokanatha Rai, K.M.; Veeresh, B. Synthesis, characterization, antidepressant and antioxidant activity of novel piperamides bearing piperidine and piperazine analogues. Bioorg. Med. Chem. Lett., 2012, 22, 7065-7070.
229. Kálai, T.; Balog, M.; Szabó, A.; Gulyás, G.; Jeko, J.; Sümegi, B.; Hideg, K. New poly(ADP-ribose) polymerase-1 inhibitors with antioxidant activity based on 4-carboxamidobenzimidazole-2- ylpyrroline and tetrahydropyridine nitroxides and their precursors. J. Med. Chem., 2009, 52, 1619-1629.
230. Neochoritis, C.G.; Zarganes-Tzitzikas, T.; Tsoleridis, C.A. One-pot microwave assisted synthesis under green chemistry conditions, antioxidant screening, and cytotoxicity assessments of benzimidazole Schiff bases and pyrimido[1,2-a]benzimidazol- 3(4H)-ones. Eur. J. Med. Chem., 2011, 46, 297.
231. Kalai, T.; Balog, M.; Szabo, A.; Gulyas, G.; Jeko, J.; Sumegi, B.; Hideg, K. New poly(ADP-ribose) polymerase-1 inhibitors with antioxidant activity based on 4-carboxamidobenzimidazole-2- ylpyrroline and -tetrahydropyridine nitroxides and their precursors. J. Med. Chem., 2009, 52, 1619.
232. Zhang, X.; Urbanski, M.; Patel, M.; Zeck, R.E.; Cox, G.G.; Bian, H.; Conway, B.R. Demarest, K.T. Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1. Bioorg. Med. Chem. Lett., 2005, 15, 5202.
233. Kim, R.M.; Chang, J.; Lins, A.R.; Brady, E.; Candelore, M.R.; Dallas-Yang, Q.; Ding, V. Discovery of potent, orally active benzimidazole glucagon receptor antagonists. Bioorg. Med. Chem. Lett., 2008, 18, 3701.
234. Ishikawa, M.; Nonoshita, K.; Ogino, Y.; Nagae, Y.; Tsukahara, D. Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators. Bioorg. Med. Chem. Lett., 2009, 19, 4450.
235. Hauel, N.H.; Nar, H.; Priepke, H.; Ries, U.; Stassen, J.M.; Wienen, W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J. Med. Chem., 2002, 45, 1757.
236. Takeuchi, K.; Bastian, J.A.; Gicord-Moore, D.S. 1,2-Disubstituted indole, azaindole and benzimidazole derivatives possessing amine moiety: a novel series of thrombin inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 2347.
237. Zhao, Z.; Arnaiz, D.; Griedel, B.; Sakata, S. Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 963.
238. Shaw, K.J.; Guilford, W.J.; Griedel, B.D.; Sakata, S.; Trinh, L.; Wu, S.; Xu, W.; Zhao, Z.; Morrissey, M.M. Benzimidazole-based fXa inhibitors with improved thrombin and trypsin selectivity. Bioorg. Med. Chem. Lett., 2002, 12, 1311.
239. Ueno, H.; Katoh, S.; Yokota, K.; Hoshi, J.I.; Hayashi, M.; Uchida, I.; Aisaka, K.; Hase, Y.; Cho, H. Structure-activity relationships of potent and selective factor Xa inhibitors: benzimidazole derivatives with the side chain oriented to the prime site of factor Xa. Bioorg. Med. Chem. Lett., 2004, 14, 4281.
240. Kolesnikov, A.; Rai, R.; Young, W.B.; Mordenti, J.; Liu, L.; Torkelson, S.; Shrader, W. D.; Leahy, E.M.; Hu, H.; Gjerstad, E.; Janc, J.; Katz, B.A.; Sprengeler, A.P. Factor VIIa inhibitors: improved pharmacokinetic parameters. Bioorg. Med. Chem. Lett., 2006, 16, 2243.
241. Hashimoto, K.; Tatsuta, M.; Kataoka, M.; Yasoshima, K. Benzimidazole derivatives as novel nonpeptide luteinizing hormonereleasing hormone (LHRH) antagonists. Part 1: Benzimidazole-5- sulfonamides. Bioorg. Med. Chem. Lett., 2005, 15, 799.
242. Li, Y.; Kataoka, M.; Tatsuta, M.; Yasoshima, K.; Yura, T. Benzimidazole derivatives as novel nonpeptide luteinizing hormonereleasing hormone (LHRH) antagonists. Part 2: Benzimidazole-5- sulfonamides. Bioorg. Med. Chem. Lett., 2005, 15, 805.
243. Tatsuta, M.; Kataoka, M.; Yasoshima, K.; Sakakibara, S. Benzimidazoles as non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 3: Discovery of 1-(1Hbenzimidazol- 5-yl)-3-tert-butylurea derivatives. Bioorg. Med. Chem. Lett., 2005, 15, 2265.
244. Pelletier, J.C.; Chengalvala, M.; Cottom, J. 2-phenyl-4- piperazinylbenzimidazoles: orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor. Bioorg. Med. Chem. Lett., 2008, 16, 6617.
245. Hauze, D.B.; Chengalvala, M.V.; Cottom, J.E.; Feingold, I.B. Small molecule antagonists of the gonadotropin-releasing hormone (GnRH) receptor: structure-activity relationships of small heterocyclic groups appended to the 2-phenyl-4-piperazinylbenzimidazole template. Bioorg. Med. Chem. Lett., 2009, 19, 1986.
246. Terefenko, E.A.; Kern, J.; Fensome, A.; Wrobel, J.; Zhu, Y.; Cohen, J.; Winneker, R.; Zhangb, Z.; Zhanga, P. SAR studies of 6- aryl-1,3-dihydrobenzimidazol-2-ones as progesterone receptor antagonists. Bioorg. Med. Chem. Lett., 2005, 15, 3600.
247. Zhang, P.; Terefenko, E.; Kern, J.; Fensome, A.; Trybulski, E.; Unwalla, R. 5-(3-Cyclopentyl-2-thioxo-2,3-dihydro-1Hbenzimidazol- 5-yl)-1-methyl-1H-pyrrole-2-carbonitrile: A novel, highly potent, selective, and orally active non-steroidal progesterone receptor agonist. Bioorg. Med. Chem., 2007, 15, 6556.
248. Ng, R.A.; Lanter, J.C.; Alford, V.C.; Allan, G.F.; Sbriscia, T.; Lundeen, S.G.; Sui, Z. Synthesis of potent and tissue-selective androgen receptor modulators (SARMs): 2-(2,2,2)-Trifluoroethylbenzimidazole scaffold. Bioorg. Med. Chem. Lett., 2007, 17, 1784.
249. Sessions, E.H.; Yin, Y.; Bannister, T.D.; Weiser, A.; Griffin, E.; Pocas, J. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase. Bioorg. Med. Chem. Lett., 2008, 18, 6390.
250. Sessions, E.H.; Smolinski, M.; Wang, B.; Frackowiak, B.; Chowdhury, S.; Yin, Y.; Chen, Y.T.; Ruiz, C.; Lin, L.; Pocas, J.; Schroter, T.; Cameron, M.D.; LoGrasso, P.; Feng, Y.; Bannister, T.D. The development of benzimidazoles as selective rho kinase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 1939.